Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo and Kaleida Health, 3 Gates Circle, Buffalo, New York 14209, USA.
Eur J Endocrinol. 2011 Jul;165(1):77-84. doi: 10.1530/EJE-11-0330. Epub 2011 Jun 6.
To determine whether the addition of liraglutide to insulin to treat patients with type 1 diabetes leads to an improvement in glycemic control and diminish glycemic variability.
In this study, 14 patients with well-controlled type 1 diabetes on continuous glucose monitoring and intensive insulin therapy were treated with liraglutide for 1 week. Of the 14 patients, eight continued therapy for 24 weeks.
In all the 14 patients, mean fasting and mean weekly glucose concentrations significantly decreased after 1 week from 130±10 to 110±8 mg/dl (P<0.01) and from 137.5±20 to 115±12 mg/dl (P<0.01) respectively. Glycemic excursions significantly improved at 1 week. The mean s.d. of glucose concentrations decreased from 56±10 to 26±6 mg/dl (P<0.01) and the coefficient of variation decreased from 39.6±10 to 22.6±7 (P<0.01). There was a concomitant fall in the basal insulin from 24.5±6 to 16.5±6 units (P<0.01) and bolus insulin from 22.5±4 to 15.5±4 units (P<0.01). In patients who continued therapy with liraglutide for 24 weeks, mean fasting, mean weekly glucose concentrations, glycemic excursions, and basal and bolus insulin dose also significantly decreased (P<0.01). HbA1c decreased significantly at 24 weeks from 6.5 to 6.1% (P=0.02), as did the body weight by 4.5±1.5 kg (P=0.02).
Liraglutide treatment provides an additional strategy for improving glycemic control in type 1 diabetes. It also leads to weight loss.
确定将利拉鲁肽添加到胰岛素中治疗 1 型糖尿病患者是否会改善血糖控制并减少血糖变异性。
在这项研究中，14 名接受连续血糖监测和强化胰岛素治疗的血糖控制良好的 1 型糖尿病患者接受利拉鲁肽治疗 1 周。在这 14 名患者中，有 8 名继续治疗 24 周。
在所有 14 名患者中，1 周后空腹和每周平均血糖浓度分别从 130±10 降至 110±8mg/dl（P<0.01）和从 137.5±20 降至 115±12mg/dl（P<0.01）。血糖波动在 1 周时明显改善。血糖浓度的平均标准差从 56±10 降至 26±6mg/dl（P<0.01），变异系数从 39.6±10 降至 22.6±7（P<0.01）。基础胰岛素从 24.5±6 降至 16.5±6 单位（P<0.01），而 bolus 胰岛素从 22.5±4 降至 15.5±4 单位（P<0.01）。在继续接受利拉鲁肽治疗 24 周的患者中，空腹、每周平均血糖浓度、血糖波动以及基础和 bolus 胰岛素剂量也明显降低（P<0.01）。24 周时 HbA1c 从 6.5%显著下降至 6.1%（P=0.02），体重也下降了 4.5±1.5kg（P=0.02）。
利拉鲁肽治疗为改善 1 型糖尿病患者的血糖控制提供了另一种策略。它还导致体重减轻。
